Table 1.
Clinical characteristics of 52 patients with advanced melanoma treated with anti-PD-1 inhibitors.
| Number of Patients (%) | |
|---|---|
| Number of patients | 52 (100%) |
| Age at diagnosis (median and range) | 66 (33–88) |
| Age at diagnosis (mean) | 64 |
| Gender | |
| Male | 35 (67.3%) |
| Female | 17 (32.6%) |
| BRAF mutation | |
| Positive | 15 (28.8%) |
| Negative | 29 (55.8%) |
| Unknown | 8 (15.4%) |
| Anti-PD-1 treatment | |
| Pembrolizumab | 27 (52%) |
| Nivolumab | 25 (48%) |
| Best response to anti-PD-1 | |
| CR | 11 (21.2%) |
| PR | 13 (25%) |
| PD | 10 (19.2%) |
| SS | 13 (25%) |
| Non-evaluable | 5 (9.6%) |
| Toxicity to anti-PD-1 treatment | |
| Yes | 10 (19.3%) |
| No | 30 (57.7%) |
| Unknown | 12 (23%) |